PMID- 12395338
OWN - NLM
STAT- MEDLINE
DCOM- 20021209
LR  - 20221207
IS  - 0270-9139 (Print)
IS  - 0270-9139 (Linking)
VI  - 36
IP  - 5
DP  - 2002 Nov
TI  - Southeast Asian patients with chronic hepatitis C: the impact of novel genotypes 
      and race on treatment outcome.
PG  - 1259-65
AB  - Hepatitis C virus (HCV) genotype and other host and viral factors influence 
      treatment outcome in chronic HCV infection. We evaluated the effect of race and 
      genotype on interferon and ribavirin treatment outcome in 70 Southeast Asian 
      (SEA) and 50 white patients. Genotype was based on the 5' untranslated region 
      (5'UTR) with a commonly used line probe assay (INNO-LiPA HCV II) that may mistype 
      genotype 7, 8, or 9 as 1b. HCV core region sequencing resulted in 
      reclassification of 8 genotype 1 and 25 genotype 1b SEA subjects as genotype 7, 
      8, or 9. Twenty-six SEA genotype 7, 8, and 9 (79%) and 10 SEA true genotype 1b 
      (59%) patients achieved a sustained virologic response (SVR) compared with 15 
      (34%) white genotype 1b patients. Logistic regression analysis showed that SEA 
      patients with genotype 7, 8, or 9 were more likely to achieve a SVR than white 
      genotype 1b patients (OR 16.56; 95%CI 4.16, 65.91) as were SEA true genotype 1b 
      patients compared with white genotype 1b patients (OR 4.63; 95%CI 1.19, 18.04). 
      In conclusion, a proportion of SEA patients classified by INNO-LiPA as genotype 
      1b were in reality genotype 7, 8, or 9. In comparison with white genotype 1b 
      patients, both SEA genotype 1b and SEA genotype 7, 8, and 9 patients showed a 
      significantly greater SVR. HCV core sequencing was necessary to determine 
      genotype accurately in persons potentially exposed to HCV genotypes 7, 8, or 9. 
      This study also supports the concept that race and ethnicity are important 
      determinants of treatment outcome in HCV infected patients.
FAU - Dev, Anouk T
AU  - Dev AT
AD  - Monash University Department of Medicine, Monash Medical Centre, Melbourne, 
      Australia. Anouk.Dev@med.monash.edu.au
FAU - McCaw, Rhonda
AU  - McCaw R
FAU - Sundararajan, Vijaya
AU  - Sundararajan V
FAU - Bowden, Scott
AU  - Bowden S
FAU - Sievert, William
AU  - Sievert W
LA  - eng
PT  - Journal Article
PT  - Research Support, Non-U.S. Gov't
PL  - United States
TA  - Hepatology
JT  - Hepatology (Baltimore, Md.)
JID - 8302946
RN  - 0 (Antiviral Agents)
RN  - 0 (Interferon alpha-2)
RN  - 0 (Interferon-alpha)
RN  - 0 (Recombinant Proteins)
RN  - 0 (Viral Core Proteins)
RN  - 49717AWG6K (Ribavirin)
SB  - IM
MH  - Adult
MH  - Antiviral Agents/*therapeutic use
MH  - Asia, Southeastern
MH  - Asian People/genetics
MH  - Female
MH  - Genotype
MH  - Hepacivirus/genetics
MH  - Hepatitis C, Chronic/*drug therapy/ethnology/*genetics
MH  - Humans
MH  - Interferon alpha-2
MH  - Interferon-alpha/*therapeutic use
MH  - Logistic Models
MH  - Male
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Recombinant Proteins
MH  - Ribavirin/therapeutic use
MH  - Treatment Outcome
MH  - Viral Core Proteins/genetics
EDAT- 2002/10/24 04:00
MHDA- 2002/12/10 04:00
CRDT- 2002/10/24 04:00
PHST- 2002/10/24 04:00 [pubmed]
PHST- 2002/12/10 04:00 [medline]
PHST- 2002/10/24 04:00 [entrez]
AID - S0270913902001465 [pii]
AID - 10.1053/jhep.2002.36781 [doi]
PST - ppublish
SO  - Hepatology. 2002 Nov;36(5):1259-65. doi: 10.1053/jhep.2002.36781.